• NewAmsterdam Pharma, Menarini won a positive CHMP opinion backing EU marketing authorization for Ubeslo (obicetrapib) and Evlarco (obicetrapib/ezetimibe).
• Recommendation covers primary hypercholesterolemia, including heterozygous familial hypercholesterolemia.
• European Commission decision expected in 2H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief via PR Newswire (Ref. ID: FR11730) on July 25, 2026, and is solely responsible for the information contained therein.